Sign in
Not yet taking people in NetherlandsPhase 2

Tests obinutuzumab in people with Sjögren's syndrome

Tests whether obinutuzumab clears harmful B cells from tissues in adults with Sjögren's syndrome.

Key facts

Who runs it
Radboud universitair medisch centrum Stichting
Where
Nijmegen, NetherlandsSee the site
Registry title
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
Status
Not yet recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
1 Jan 2026
Expected to end
1 Jan 2028
Type of study
Interventional
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary Sjögren's syndrome who have certain antibodies and signs of higher risk of lymphoproliferative disease. They must agree to tissue biopsies.

Age
18 years or older
Sex
All sexes
Disease stage
Primary Sjögren's syndrome meeting the EULAR/ACR 2016 classification criteria, with cryoglobulinemia and/or predictors of lymphoproliferative disease (for example rheumatoid factor antibodies, a history of lymphadenopathy, salivary gland swelling or purpuric lesions, or a lymphocytic focus score ≥ 3).
Earlier treatment
No earlier Obinutuzumab. No rituximab or other anti-CD20 therapy in the last 9 months. If it was 9-12 months ago, CD19+ B-cell count in blood must be at least 80 cells/microliter. No biologic or targeted synthetic DMARDs at the same time.
Biomarker or test result
ANA, anti-Ro60 and anti-La antibodies present.

Main reasons for not taking part

  • Active infection or other active inflammatory condition
  • Positive test for hepatitis B, hepatitis C or HIV
  • Active tuberculosis, tuberculosis treated in the last 3 years, or untreated latent tuberculosis
  • Positive pregnancy test or breast feeding
  • Prednisone above 10 mg by mouth, or a change in prednisone dose in the last 4 weeks

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • adult patients, age ≥ 18 years
  • patients with with primary SjS fulfilling the EULAR/ACR 2016 classification criteria
  • Presence of ANA, anti-Ro60, anti-La
  • Cryoglobulinemia and/or previous predictors for development lymphoproliferative disease. These consist of at least one of the following: - detectable rheumatoid factor antibodies - a history of lymphadenopathy - a history of salivary gland swelling - a history of purpuric lesions or biopsy-proven vasculitis - a lymphocytic focus score ≥ 3 in a salivary gland biopsy performed for diagnosis or for screening
  • In female patients: use of reliable method of contraception during the study and at least until 18 months after the last injection, in women of child bearing potential
  • signed written informed consent
  • Willingness to undergo study procedures, including tissue biopsies as described in the informed consent

Who cannot take part

  • presence of active concurrent inflammatory or infectious condition
  • Necessity to immunize with live or attenuated viral vaccines during treatment with Obinutuzumab and until B-cell recovery
  • previous experience with Obinutuzumab through a clinical trial or regular treatment
  • concomitant use of any biologic DMARDs etanercept, adalimumab, infliximab, anakinra, abatacept, tocilizumab, certolizumab, golimumab) or targeted synthetic DMARDs tofacitinib, baracitinib or filgotinib
  • concurrent treatment with prednisone > 10 mg orally
  • change in prednisone dosage within 4 weeks before the baseline visit
  • change in prednisone dosage within 4 weeks before the baseline visit
  • treatment with intra-muscular, intra-articular or intravenous prednisone 4 weeks before the baseline visit
  • positive serology for hepatitis B, C or Human Immunodeficiency Virus
  • uncooperative or any condition that could make the patient potentially noncompliant to the study procedures, etc, and, as applicable in the Netherlands, individuals who are institutionalized due to regulatory or legal order
  • opportunistic infection in the preceding 3 months
  • Subjects with a history of active TB treated within the last 3 years
  • liver cirrhosis or severe renal insufficiency
  • treatment with rituximab or any other anti-CD20 therapy < 9 months before inclusion. - In patients treated with rituximab or any other anti-CD20 therapy 9-12 months before inclusion: A CD19+ B-cell count in peripheral blood of < 80 cells/microliter
  • Subjects with current clinical or laboratory evidence of active tuberculosis(TB)
  • patients for whom Obinutuzumab is contra-indicated as described in the local label (SmPc)
  • patients currently participating in any interventional clinical trials
  • positive pregnancy test or breast feeding
  • Subjects with untreated latent TB
  • heavy alcohol consumption (>3 drinks/day)

Where in Netherlands

  • Radboud universitair medisch centrum StichtingNijmegen, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To analyze if Obinutuzumab induces depletion of anti-nuclear antibody producing and rheumatoid factor B cells in affected tissues of patients with SjS.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
Plain-language title
Tests obinutuzumab in people with Sjögren's syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 September 2026